Metagenomi Therapeutics Aktie
Marktkapitalisierung
33,73 Mio. $
33,73 Mio. $
Streubesitz
61,71%
KGV
-1,02
Index-Zuordnung
-
Metagenomi, Inc. Common Stock Unternehmensprofil
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The companys lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. im Januar 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Vorstand
Dr. Jian Irish M.B.A., Ph.D.
CEO, President & Director
Frau Pamela M. Wapnick M.B.A.
Chief Financial Officer
Herr Matthew L. Wein J.D.
General Counsel, Compliance Officer, Leiter BD&L und Corporate Secretary
Dr. Joseph Knowles M.D.
Co-Founder & Member of Scientific Advisory Board
Herr Mark Leonard
Senior Vice President of Technical Development und Operations
Dr. Alan Brooks Ph.D.
Senior Vice President of Research
Frau Katalin Kauser M.D., Ph.D.
Senior Vice President of Translational Biology
Herr Nikhil Bhide M.B.A.
Senior Vice President of Business Development
Aktionärsstruktur
67,612%
Freefloat
49,082%
Individuelle Aktionäre
18,53%
Institutionelle Aktionäre
Unternehmenstermine
Stammdaten
| Nennwert/Aktie | - |
| Land | USA |
| Währung | USD |
| Branche | Biotechnologie |
| Aktientyp | - |
| Sektor | Gesundheit |
| Gattung | - |
Quelle: Leeway